Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 20 recruiting now early-phase tilt

Type 2 Diabetes Mellitus (T2DM): early-phase trial registry

20 of 25 indexed Type 2 Diabetes Mellitus (T2DM) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #652 of 28,707 conditions by registered trial count.

25 US clinical trials · 20 currently recruiting · #652 of 28,707 conditions by registered trial count

Type 2 Diabetes Mellitus (T2DM): 25 US clinical trials tracked, 20 recruiting.

Type 2 Diabetes Mellitus (T2DM) is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Alnylam Pharmaceuticals, running 2 of these trials.

Enrollment posture brief

Registry condition type-2-diabetes-mellitus-t2dm

OPEN 20 | RECR 80% | LATE 2 | EARLY 8 | RANK #652 | SPON 2

Nearest open-share peer: Ablation (80% recruiting · 5 trials)

Type 2 Diabetes Mellitus (th…80%Alpha-1 Antitrypsin Deficien48%Alcohol Use40%Acute Lymphocytic Leukemia36%Alcohol-Related Disorders36%
Open-enrollment share among volume-matched conditions near Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus (T2DM) lists 20 open slots (80% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Type 2 Diabetes Mellitus (T2DM) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Type 2 Diabetes Mellitus (T2DM) is recruiting above its size-band peers.

    20 of 25 indexed trials (80%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Type 2 Diabetes Mellitus (T2DM) trials is spread across many organizations.

    Alnylam Pharmaceuticals accounts for 2 of 25 trials (8%). 22 distinct sponsors appear on at least one study for this condition label.

  3. Typical Type 2 Diabetes Mellitus (T2DM) enrolment sits around 144 participants.

    Median target enrolment is 144 among the 25 trials that report a genuine target (sentinel values excluded). 11 of those (44%) plan for fewer than 100 participants.

  4. Type 2 Diabetes Mellitus (T2DM) research is mostly interventional.

    23 interventional and 2 observational studies make up this index (92% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 27Phase 31Phase 41

Open and recent trials

25 total, page 1 of 1

RECRUITING 7,000 participants

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

Clindove Research

NCT07106879

RECRUITING NA 1,250 participants

Achieving Routine Intervention and Screening for Emotional Health

University of Chicago

NCT06887049

RECRUITING NA 750 participants

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Duke University

NCT06906627

RECRUITING NA 564 participants

CGM for Management of Type 2 Diabetes in Pregnancy

University of Alabama at Birmingham

NCT06628453

RECRUITING NA 420 participants

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

Duke University

NCT06906640

RECRUITING NA 216 participants

The GRoceries Aimed at Increasing Nutrition Study

University of Pennsylvania

NCT07167004

RECRUITING NA 200 participants

Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED

Rutgers, The State University of New Jersey

NCT06899191

RECRUITING NA 200 participants

Human Immunodeficiency Virus (HIV) Food Insecurities

Wake Forest University Health Sciences

NCT04943861

RECRUITING Phase 2 166 participants

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

University of Florida

NCT04501406

RECRUITING Phase 3 160 participants

RCT Glargine vs NPH for Treatment of DM in Pregnancy

Loyola University

NCT06619301

RECRUITING Phase 1 144 participants

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Alnylam Pharmaceuticals

NCT06845202

RECRUITING NA 80 participants

Groceries Plus Multi-Component Lifestyle Intervention for Adults With Hypertension and Type 2 Diabetes

Johns Hopkins University

NCT06921356

RECRUITING NA 70 participants

CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes

Thomas Jefferson University

NCT07184775

RECRUITING NA 60 participants

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

Vanderbilt University Medical Center

NCT06852950

RECRUITING NA 40 participants

Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations

Diabetes Solutions International

NCT06939413

RECRUITING NA 40 participants

Continuous Glucose Monitoring for Self-Management of Type 2 Diabetes in Young Adults

San Diego State University

NCT07065721

RECRUITING Phase 2 40 participants

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

Alnylam Pharmaceuticals

NCT07465224

RECRUITING 36 participants

Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D

University of Colorado, Denver

NCT07005362

RECRUITING Phase 2 30 participants

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

Estar Medical dba Medical Technologies

NCT06810726

RECRUITING NA 30 participants

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

Stanford University

NCT06836479

ACTIVE NOT RECRUITING Phase 2 409 participants

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Amgen

NCT06660173

ACTIVE NOT RECRUITING Phase 2 360 participants

A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Carmot Therapeutics

NCT06628362

ACTIVE NOT RECRUITING Phase 2 133 participants

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Metsera, a wholly owned subsidiary of Pfizer

NCT06897202

ACTIVE NOT RECRUITING Phase 2 70 participants

Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation

HiDO Technologies

NCT06691256

COMPLETED Phase 4 61 participants

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

University of Florida

NCT03774394

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 7
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Type 2 Diabetes Mellitus (T2DM) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
ALN-4324 Drug
2 trials
Continuous glucose monitor Device
2 trials
Clopidogrel active metabolite Drug
1 trials
HiDO-ALZ Device
1 trials
CT-388 Drug
1 trials
MET097 Injection Drug
1 trials
Blood Work Other
1 trials

US sites by state

Facility locations filed on Type 2 Diabetes Mellitus (T2DM) trials. A trial with sites in several states counts in each.

Florida 8 trials
California 7 trials
Texas 6 trials
North Carolina 6 trials
Illinois 5 trials
Alabama 5 trials
Pennsylvania 3 trials
New Jersey 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Type 2 Diabetes Mellitus (T2DM) page

25 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 20 Type 2 Diabetes Mellitus (T2DM) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Alnylam Pharmaceuticals sponsors the most Type 2 Diabetes Mellitus (T2DM) trials on record, review their full trial history before evaluating a specific study. See Alnylam Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 2 Diabetes Mellitus (T2DM) condition card totals 25 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.